Table 1 |
||||
|
Characteristics of study populations |
||||
| Parameter |
Normal |
RA |
SLE |
SLE repeat |
|
|
||||
| Number of subjects |
30 |
60 |
60 |
37 |
| Age (mean [range]; years) |
36.5 (21.2–54.4) |
47.3 (19.1–71.7) |
39.4 (19.4–66.8) |
35.1 (20.4–66.3) |
| Sex (female/male; n) |
27/3 |
52/8 |
56/4 |
36/1 |
| Race (n) |
||||
| Asian |
11 |
5 |
5 |
2 |
| Black |
3 |
3 |
6 |
3 |
| Hispanic |
13 |
51 |
49 |
32 |
| White |
3 |
1 |
0 |
0 |
| Prednisone use |
||||
| Number of patients |
- |
17 |
50 |
31 |
| Mean dosage (mg/day) |
- |
5.5 |
10.8 |
6.0 |
| Dosage range (mg/day) |
- |
2.5–10 |
2–30 |
1–30 |
| Use of other medications (n) |
||||
| Cyclophosphamide |
- |
0 |
4 |
2 |
| Azathioprine |
- |
4 |
27 |
15 |
| Mycophenolate mofetil |
- |
1 |
9 |
13 |
| Methotrexate |
- |
42 |
2 |
2 |
| Sulfasalazine |
- |
17 |
0 |
0 |
| Hydroxychloroquine |
- |
36 |
53 |
36 |
| Leflunomide |
- |
0 |
1 |
0 |
| Any TNF antagonist |
- |
18 |
0 |
0 |
|
|
||||
|
RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TNF, tumor necrosis factor. |
||||
|
Collins et al. Arthritis Research & Therapy 2006 8:R6 doi:10.1186/ar1855 |
||||
